Viking Therapeutics (VKTX) Gains from Investment Securities (2014 - 2026)

Viking Therapeutics has disclosed Gains from Investment Securities across 13 years of filings, most recently posting $5.9 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $5.9 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $5.9 million (changed N/A YoY), and the FY2025 annual result was $5.1 million, up 18669.74% from the prior year.
• Gains from Investment Securities came in at $5.9 million for Q1 2026 at Viking Therapeutics, up from $41000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $42.1 million in Q1 2024 to a low of $15000.0 in Q1 2022.
• The 5-year median for Gains from Investment Securities is $5.0 million (2024), against an average of $9.3 million.
• Across the five-year window, Gains from Investment Securities surged 17103.69% in 2023 and tumbled 99.9% in 2025, its largest moves.
• Viking Therapeutics' Gains from Investment Securities stood at $30000.0 in 2022, then soared by 17103.69% to $5.2 million in 2023, then surged by 713.59% to $42.0 million in 2024, then sank by 99.9% to $41000.0 in 2025, then soared by 14385.4% to $5.9 million in 2026.
• The last three Gains from Investment Securities figures came in at $5.9 million (Q1 2026), $41000.0 (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.